Oncolytics Biotech (ONCY) Stock Rating Reiterated at Buy
Published on 5/26/2026
AI Summary
Summarized by AI from the source belowH.C. Wainwright has reiterated its buy rating for Oncolytics Biotech (ONCY). The firm stated that they continue to see potential in the company's product pipeline. This rating is expected to influence investor sentiment positively. Oncolytics Biotech is actively involved in the development of therapies for cancer, which could impact future market performance based on clinical results.
Get the free market brief
Top stories and analysis, summarized. No spam, unsubscribe anytime.
Related News
Earnings
Top Dividend Stocks: Realty Income (O) at 5.1% Yield, Comcast (CMCSA) at 5.6%
Jul 10
Earnings
Wingstop (WING) Grows by 382 Locations, Surpassing Competitors
Jul 10
Earnings
Delta (DAL) Forecasts Q3 Earnings of $2.00 to $2.50 Per Share
Jul 10
Earnings
Niagen Bioscience Stock Rating Reiterated by Canaccord Amid Drug Launch
Jul 10